Pfizer vaccine price move in US could add $3bn to annual revenues       

The drugmaker is attempting to as much as quadruple its current US prices

Pfizer said that it is targeting a range of $110 to $130 per dose for its Covid-19 vaccine once the US moves to a commercial market next year.

Pfizer's attempt to as much as quadruple its current US prices for its Covid-19 vaccines could spur revenues for years, analysts said.

The drugmaker, which developed and sells the vaccine with Germany's BioNTech, said that it is targeting a range of $110 to $130 a dose for the vaccine once the US moves to a commercial market next year.